Abstract

GLP-1 receptor agonists stimulate insulin secretion from pancreatic β-cells, suppress glucagon secretion, delay gastric emptying, and reduce appetite. They lower fasting and postprandial blood sugar. They are administered by injection-subcutaneously. The aim of the present analysis was to investigate the level of glycemic control in patients with type 2 diabetes mellitus treated with GLP-1 receptor agonists.  Of a total of 66 patients treated with a GLP-1 receptor agonist, 26 were male (39.4%) and 40 were female (60.6%) Analyzing the data from our study, a favorable, statistically significant reduction in both preprandial and postprandial blood glucose was reported at each follow-up stage after 6 months of treatment with GLP-1 receptor agonists. In glycated hemoglobin, a statistically significant reduction was found logically on the result of the blood sugar profile after 6 months of treatment with GLP-1 receptor agonists.

Key words: type 2 diabetes mellitus, GLP-1 receptor agonists, glycemic control

Download full text as PDF file